Hajduga-Szewczyk Marta, Smedowski Adrian, Filipecka Iwona, Mrukwa-Kominek Ewa
Department of Ophthalmology, Professor K. Gibinski University Clinical Center, Medical University of Silesia, Katowice, Poland.
Okulus Plus Co, Bielsko-Biala, Poland.
Front Med (Lausanne). 2023 Nov 23;10:1273889. doi: 10.3389/fmed.2023.1273889. eCollection 2023.
Micro-invasive glaucoma surgery involves a group of treatment methods associated with a low rate of side effects and good effectiveness outcomes. One of the most frequently performed procedures belonging to this group is iStent microstent implantation. The aim of this study was to perform a retrospective evaluation of the safety and efficacy of a combined procedure involving cataract phacoemulsification and single iStent microstent implantation, performed simultaneously.
The complete medical records of 62 patients (91 eyes) were analyzed retrospectively, including the best corrected visual acuity, intraocular pressure, the mean defect of visual fields, and the number of active substances used in eye drops. The follow-up times were 1, 3, 6, 9, and 12 months after the surgical procedure.
A significant improvement in the best corrected visual acuity and a reduction of the intraocular pressure were achieved after the surgery. On average, after 12 months, the best corrected visual acuity improved from 0.70 (0.25) to 0.91 (0.18; = 0.001), the intraocular pressure reduced from 17.76 (3.95) to 14.91 (3.04; = 0.0001), and the number of active substances used in eye drops reduced from 2.07 (1.08) to 0.70 (0.06; = 0001). In addition, we found that patients who initially showed higher intraocular pressure values did not benefit from surgery in the aspect of the number of active substances used in their eye drops. Intraoperative and postoperative adverse events were transient and ultimately did not affect the outcomes.
Simultaneous cataract phacoemulsification with single iStent implantation in patients with open-angle glaucoma is a safe and effective method for reducing intraocular pressure and the number of topical medications that must be used. Having initially higher intraocular pressure values may limit the beneficial effects of iStent implantation by subordinating patients from topical treatment; thus, single iStent implantation may not be the most favorable choice in uncontrolled glaucoma cases.
微创青光眼手术涉及一组副作用发生率低且疗效良好的治疗方法。该组中最常实施的手术之一是iStent微支架植入术。本研究的目的是对白内障超声乳化吸除术与单次iStent微支架植入术同时进行的联合手术的安全性和有效性进行回顾性评估。
回顾性分析62例患者(91只眼)的完整病历,包括最佳矫正视力、眼压、视野平均缺损以及滴眼液中使用的活性物质数量。随访时间为手术后1、3、6、9和12个月。
手术后最佳矫正视力有显著改善,眼压降低。平均而言,术后12个月,最佳矫正视力从0.70(0.25)提高到0.91(0.18;P = 0.001),眼压从17.76(3.95)降至14.91(3.04;P = 0.0001),滴眼液中使用的活性物质数量从2.07(1.08)降至0.70(0.06;P = 0.001)。此外,我们发现最初眼压值较高的患者在滴眼液中使用的活性物质数量方面未从手术中获益。术中和术后不良事件是短暂的,最终未影响手术结果。
在开角型青光眼患者中同时进行白内障超声乳化吸除术与单次iStent植入术是降低眼压和减少必须使用的局部用药数量的一种安全有效的方法。最初眼压值较高可能会通过使患者依赖局部治疗而限制iStent植入的有益效果;因此,在未控制的青光眼病例中,单次iStent植入可能不是最有利的选择。